logo

Astrazeneca Plc (AZN)



Trade AZN now with
  Date
  Headline
8/26/2021 2:12:17 AM AstraZeneca: Forxiga Approved In Japan For Chronic Kidney Disease In Patients With And Without Type-2 Diabetes
8/26/2021 2:05:46 AM AstraZeneca Says ALXN1840 FoCus Phase III Trial In Wilson Disease Meets Primary Endpoint
8/20/2021 2:06:33 AM AstraZeneca Says AZD7442 Prophylaxis Trial Meets Primary Endpoint
8/9/2021 2:22:22 AM AstraZeneca's Forxiga Approved In The EU For Chronic Kidney Disease In Patients With And Without Type-2 Diabetes
8/9/2021 2:04:55 AM AstraZeneca Says Enhertu Head-to-head DESTINY-Breast03 Phase III Trial Meets Primary Endpoint
8/2/2021 2:09:14 AM AstraZeneca Says Saphnelo Approved In The US For Moderate To Severe Systemic Lupus Erythematosus
7/29/2021 2:06:27 AM AstraZeneca Posts H1 Revenue Growth Of 23% To $15.54 Bln
7/26/2021 2:05:08 AM Alexion’ Ultomiris Recommended For Authorization In EU For Expanded Use To Include Children & Adolescents With PNH
7/23/2021 7:04:53 AM AstraZeneca: FDA Approves BYDUREON BCise In US For Type 2 Diabetes In Patients Ages 10 Years And Older